platinum has been researched along with fluorodeoxyglucose f18 in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Backhouse, CJ; Gagnon, K; McQuarrie, SA; Sant, E; Wilson, JS | 1 |
| Aboagye, EO; Gabra, H; Perumal, M; Stronach, EA | 1 |
| Ball, DL; Chabrot, M; Everitt, SJ; Hicks, RJ; Leimgruber, A; MacManus, M; Möller, A; Solomon, B | 1 |
| Behnia, S; Cassaday, RD; Gopal, AK; Graf, SA; Green, DJ; Holmberg, L; Libby, EN; Maloney, DG; Onishi, M; Pagel, JM; Philip, M; Press, OW; Roden, JE; Schiavo, K; Shustov, AR; Smith, SD; Till, BG | 1 |
| Gallamini, A; Kostakoglu, L | 1 |
| Agarwal, KK; Bhalla, AS; Das, CJ; Kumar, R; Mohan, A; Pandey, AK; Patel, CD; Sekhar Bal, C; Sharma, A; Sharma, MC; Sharma, P; Vishnubhatla, S | 1 |
1 trial(s) available for platinum and fluorodeoxyglucose f18
| Article | Year |
|---|---|
Effect of Platinum-Based Chemoradiotherapy on Cellular Proliferation in Bone Marrow and Spleen, Estimated by (18)F-FLT PET/CT in Patients with Locally Advanced Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Marrow Cells; Carcinoma, Non-Small-Cell Lung; Cell Count; Cell Proliferation; Chemoradiotherapy; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Glucose; Humans; Lung Neoplasms; Male; Middle Aged; Neutrophils; Organ Specificity; Platinum; Positron-Emission Tomography; Spleen; Tomography, X-Ray Computed | 2014 |
5 other study(ies) available for platinum and fluorodeoxyglucose f18
| Article | Year |
|---|---|
Assessing the performance and longevity of Nb, Pt, Ta, Ti, Zr, and ZrO₂-sputtered Havar foils for the high-power production of reactive [18F]F by proton irradiation of [18O]H2O.
Topics: Cyclotrons; Fluorodeoxyglucose F18; Microscopy, Electron, Scanning; Niobium; Platinum; Protons; Tantalum; Titanium; Water; Zirconium | 2011 |
Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose- and 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography as biomarkers of therapy response in platinum-resistant ovarian cancer.
Topics: Animals; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Chlorpropamide; Dideoxynucleosides; Drug Resistance, Neoplasm; Female; Fluorodeoxyglucose F18; Humans; Ki-67 Antigen; Mice; Ovarian Neoplasms; Platinum; Positron-Emission Tomography; Time Factors; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status.
Topics: Adolescent; Adult; Brentuximab Vedotin; Female; Fluorodeoxyglucose F18; Hodgkin Disease; Humans; Immunoconjugates; Male; Middle Aged; Platinum; Positron-Emission Tomography; Prognosis; Treatment Outcome; Young Adult | 2015 |
Metabolic Tumor Volume: We Still Need a Platinum-Standard Metric.
Topics: Antineoplastic Agents; Disease-Free Survival; Fluorodeoxyglucose F18; Platinum; Tumor Burden | 2017 |
Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies; Tumor Burden | 2018 |